<DOC>
	<DOCNO>NCT00735306</DOCNO>
	<brief_summary>The primary purpose trial define maximum tolerate and/or recommended phase II dose combination Avastin Tarceva patient undergo radiation therapy carcinoma pancreas . An additional primary objective describe frequency nature grade III/IV grade I/II toxicity associate regimen . Secondary objective include describe 1-year disease-free survival overall survival rate well estimate clinical pathologic complete response rate associate regimen .</brief_summary>
	<brief_title>Phase I/II Trial Radiation , Avastin Tarceva Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>This phase I/II study 18 patient enrolled phase I portion additional 26 patient phase II portion . Patients treat Tarceva ( cohort specify dose ) , along fix dos Avastin radiation therapy . Avastin give IV dose day 1 , 15 , 29 . Tarceva give daily mouth . On radiation day Tarceva take immediately XRT . XRT give total dose 50.4 Gy 28 fraction , fraction give daily Monday Friday 5.5 week</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age &gt; 18 year Histologically and/or cytologically confirm adenocarcinoma pancreas , T14 , N01 , M0 . Patients disease combine modality therapy indicate . Performance status 02 Life expectancy &gt; 3 month Adequate hematologic , renal , hepatic function Calculated creatinine Cl &gt; 50 mL/min Use effective mean contraception patient childbearing potential . No prior therapy pancreatic cancer Previous treatment bevacizumab erlotinib Evidence duodenal invasion gastric outlet obstruction Presence bleeding diathesis coagulopathy History prior arterial thrombotic event Conditions lead inadequate gastrointestinal tract absorption Poorly control diarrhea . Presence baseline proteinuria renal dysfunction ( CrCl &lt; 50 ( CockcroftGault equation ) Inadequately control hypertension New York Heart Association ( NYHA ) Grade II great congestive heart failure Clinically significant peripheral vascular disease Presence central nervous system brain metastasis Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Minor surgical procedure fine needle aspiration core biopsy within 7 day prior Day 0 Pregnant lactating female History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , ulcer , bone fracture Inability comply study and/or followup procedure Treatment carcinoma within last five year , except cure nonmelanoma skin cancer , curatively treat insitu cervical cancer , localize prostate cancer current PSA &lt; 1.0 mg/dL 2 successive evaluation , least 3 month apart , recent evaluation 4 week prior entry . Comorbid condition would complicate safety compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Locally advanced</keyword>
	<keyword>Unresectable</keyword>
</DOC>